Canada Gazette, Part I, Volume 153, Number 52: GOVERNMENT NOTICES

December 28, 2019

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant safety data sheet (SDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor, 4908B, Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

A Notice of Filing was published in Part I of the Canada Gazette and there were no written representations from affected parties with respect to any of the claims for exemption and related SDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

RN Claimant Product Identifier Date of Decision
9725 MacDermid Enthone, Inc. ENTHOBRITE® NCZ CONDITIONER 2019-10-03
9858 Momentive Performance Materials Niax* silicone L-854 2019-10-03
10120 Afton Chemical Corporation HiTEC® 6590 Fuel Additive 2019-06-27
10121 Afton Chemical Corporation HiTEC® 6590D Fuel Additive 2019-06-27
10287 Innospec Fuel Specialties LLC OGI-7682 2019-10-22
10323 Multi-Chem Production Chemicals Co. MultiSweet MX 8-1003 2019-09-30
10366 Halliburton Group PEN-5M 2019-09-10
10613 Ingevity Corporation EnvaDym 175 2019-10-02
11626 Secure Energy Services SECURE THERMOSOLV 16C 2019-09-20
11738 Calfrac Well Services CalSurf 9400 2019-10-10
11791 Ingevity Corporation PC-1696 2019-09-24
11889 Canadian Energy Services WRXSOL Poly CI-A 2019-10-15
11903 Americhem Clay Stabilizer LLC ACS ClayLOK 2019-10-17
12004 Dow Chemical Canada UCARSOL(TM) AP SOLVENT 800 LFG 2019-09-25
12009 Dow Chemical Canada UCARSOL(TM) AP SOLVENT 810 2019-09-25
12013 Dow Chemical Canada UCARSOL(TM) AP SOLVENT 814 2019-09-25
12063 Suez Water Technologies & Solutions Canada PETROFLO 20Y3112 2019-10-01
12081 King Industries Inc. K-KAT® XK-661 2019-07-26
12093 Suez Water Technologies & Solutions Canada LOSALT LS1521 2019-09-19
12096 Chemours Canada Company Capstone™ FS-31 2019-07-10
12155 Clean Harbours Paratene D740 2019-10-03
12172 Schlumberger PI-7316 2019-10-10
12185 Nalco Canada ULC Corsamul 800 HF 2019-09-26

The subject of the claim on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN Notice of Filing Publication Date Original Subject of the Claim Revised Subject of the Claim
10120 2016-07-30 C.i. and C. of one ingredient
C. of nine ingredients		 C.i. of one ingredient
10121 2016-07-30 C.i. and C. of one ingredient
C. of nine ingredients 		C.i. of one ingredient
11889 2018-03-10 C.i. and C. of one ingredient C.i. and C. of one ingredient
C. of one ingredient
12004 2018-05-12 C.i. and C. of one ingredient C.i. and C. of one ingredient
C. of one ingredient
12013 2018-05-12 C.i. of one ingredient
C. of two ingredients		 C.i. and C. of one ingredient
C. of one ingredient
12172 2018-07-21 C.i. and C. of one ingredient
C. of nine ingredients		 C.i. and C. of one ingredient
C. of seven ingredients

Note: C.i. = chemical identity and C. = concentration

In all cases where the SDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the SDS or the label amended as necessary.

Non-compliances that fall outside the scope of what is required to be published in the Canada Gazette are referred to as “administrative non-compliances.”

Please refer to Health Canada’s List of Active Claims for Exemption for a description of “administrative non-compliances” and their associated corrective measures.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant SDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN: 9725
Date of compliance undertaking: 2019-11-13

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the recommended use.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Correct the disclosure of misleading information regarding accidental release measures.
RN:10120
Date of compliance undertaking: 2019-10-10

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose the additional applicable common names and synonyms for the ingredients “solvent naphtha (petroleum), light aromatic” and “2-ethylhexan-1-ol”.
  3. Correct the disclosure of misleading information regarding conditions to avoid.
  4. Disclose the calculated product oral ATE value of 68 000 mg/kg (49.8% unknown) and inhalation (dust/mist) ATE value of 99 mg/L (98.5% unknown).
RN: 10121
Date of compliance undertaking: 2019-10-10

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose the additional applicable common names and synonyms for the ingredients “solvent naphtha (petroleum), light aromatic” and “2-ethylhexan-1-ol”.
  3. Disclose the appropriate precautions for safe handling.
  4. Correct the disclosure of misleading information regarding conditions to avoid.
  5. Disclose the calculated product oral ATE value of 94 000 mg/kg (42% unknown) and inhalation (dust/mist) ATE value of 99 mg/L (98.5% unknown).
RN: 10287
Date of compliance undertaking: 2019-10-24

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the Canadian initial supplier identifier.
  2. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Category 3 (Narcotic Effect)”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the percent of unknown toxicity of “70%” for the calculated product oral ATE value.
  5. Disclose “Other hazards” on the SDS.
  6. Disclose the applicable common names and synonyms for the ingredient “methanol”.
  7. Disclose an adequate product odour.
  8. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  9. Disclose the calculated product oral ATE value of 500 mg/kg (70% unknown).
  10. Disclose that the ingredient “methanol” has been shown to be an eye irritant.
  11. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 10613
Date of compliance undertaking: 2019-10-17

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose “Other hazards” on the SDS.
  3. Correct the disclosure of misleading information regarding personal protective equipment in case of accidental release.
  4. Correct the disclosure of misleading information regarding the precautions for safe handling.
  5. Disclose “eye contact” as an additional likely route of exposure.
RN: 11626
Date of compliance undertaking: 2019-11-15

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Remove CANUTEC’s emergency telephone number.
  4. Disclose the additional hazard classification of “Carcinogenicity — Category 2”.
  5. Disclose the symbol and/or name of the symbol for “Health hazard” on the SDS.
  6. Disclose the additional confidential ingredient “sodium carboxylate 2”.
  7. Correct the disclosure of misleading information regarding the precautions for safe handling.
  8. Disclose an adequate product odour.
  9. Disclose “2,2,2-trichloroethanol (chlorinated solvent), aluminum, zinc, trichloroethylene (chlorinated solvent) and tetrachoroethylene” as incompatible materials.
  10. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN : 11738
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the additional hazard classifications of “Eye Irritation — Category 2”, “Specific Target Organ Toxicity (Single Exposure) — Category 1 (eye)”, and “Specific Target Organ Toxicity (Single Exposure) — Category 3 Narcotic Effects (central nervous system)”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the additional applicable common names and synonyms for the ingredient “methanol”.
  5. Disclose “static discharge” as a condition to avoid.
  6. Disclose the calculated product oral ATE value of 1 126 mg/kg and dermal ATE value of 15 400 mg/kg.
  7. Correct the misleading information regarding the LD50 (rat, oral) and LD50 (rat, dermal) values for the ingredients “methanol” and “ethoxylated alcohols”.
RN: 11791
Date of compliance undertaking: 2019-10-17

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose “Other hazards” on the SDS.
  3. Correct the disclosure of misleading information regarding personal protective equipment in case of accidental release.
  4. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  5. Disclose the product’s flammability.
  6. Disclose “oxides of carbon” and “oxides of nitrogen” as additional hazardous decomposition products.
  7. Disclose “eye contact” as an additional likely route of exposure.
RN: 11889
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Remove CANUTEC’s emergency telephone number.
  4. Disclose the Canadian initial supplier identifier.
  5. Disclose the additional hazard classification of “Specific Target Organ Toxicity (repeated exposure) — Category 1”.
  6. Disclose “Other hazards” on the SDS.
  7. Disclose the additional applicable common names and synonyms for the ingredient “xylene”.
  8. Disclose the symptoms and effects, whether acute or delayed.
  9. Disclose an adequate product odour
  10. Disclose the product’s n-octanol/water partition coefficient.
  11. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  12. Disclose the calculated product oral ATE value of 4 757 mg/kg and inhalation (vapour) ATE value of 29 mg/L.
  13. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the ingredient “xylene”.
RN: 11903
Date of compliance undertaking: 2019-11-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the recommended use.
  3. Disclose an adequate emergency telephone number.
  4. Disclose the appropriate information under the section heading “Other Names”.
  5. Disclose the additional hazard classification of “Acute Toxicity (Oral) — Category 4”.
  6. Disclose the symbol and/or name of the symbol for “Exclamation mark” on the SDS.
  7. Disclose the information elements concerning the additional hazard and precautionary statements.
  8. Disclose the percent of unknown toxicity of “8.8%” for the calculated product oral ATE value.
  9. Disclose information on the precautions for firefighters.
  10. Disclose emergency procedures to follow in case of accidental release.
  11. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  12. Disclose an ACGIH TLV–TWA exposure limit of 1 mg/m3 and an ACGIH TLV–STEL value of 3 mg/m3 for the confidential ingredient “inorganic acid”.
  13. Correct the disclosure of misleading information regarding the incompatible materials.
  14. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  15. Disclose the calculated product oral ATE value of 1 795 mg/kg (8.8% unknown).
  16. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the confidential ingredient “inorganic acid”.
  17. Correct the disclosure of misleading information regarding the subheadings.
RN: 12004
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Remove CANUTEC’s emergency telephone number.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose the calculated product oral ATE value of 2 500 mg/kg (0% unknown) and dermal ATE value of 4 700 mg/kg (0% unknown).
  4. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value and the LD50 (rabbit, dermal) value for the ingredient “piperazine”.
  5. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  6. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 12009
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Remove CANUTEC’s emergency telephone number.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose the calculated product oral ATE value of 2 100 mg/kg and dermal ATE value of 14 000 mg/kg.
  4. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  5. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 12013
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Remove CANUTEC’s emergency telephone number.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose the calculated product oral ATE value of 2 200 mg/kg and dermal ATE value of 9 800 mg/kg.
  4. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  5. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12063
Date of compliance undertaking: 2019-11-15

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the additional hazard classification of “Acute Toxicity (Oral) — Category 4”.
  4. Disclose the applicable common names and synonyms for the ingredient “hydroquinone”.
  5. Correct the disclosure of misleading information regarding first aid measures.
  6. Disclose the nature of the hazardous combustion products.
  7. Correct the disclosure of misleading information regarding personal protective equipment.
  8. Disclose an adequate product odour.
  9. Correct the disclosure of misleading information regarding ingestion as a route of exposure.
  10. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  11. Disclose the calculated product oral ATE value of 1 764 mg/kg.
  12. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the ingredient “hydroquinone”.
  13. Disclose the date of latest revision.
RN: 12081
Date of compliance undertaking: 2019-11-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Remove CANUTEC’s emergency telephone number.
  3. Disclose the Canadian initial supplier identifier.
  4. Disclose the information elements concerning the additional hazard and precautionary statements.
  5. Disclose the percent of unknown toxicity of “57.9%” for the calculated product dermal ATE value.
  6. Disclose the nature of the hazardous combustion products.
  7. Disclose the applicable information for “conditions for safe storage, including any incompatibilities” under section 7, “Handling and storage”.
  8. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  9. Disclose an adequate product odour.
  10. Disclose “static discharge” as a condition to avoid.
  11. Disclose the calculated product oral ATE value of 2 179 mg/kg, dermal ATE value of 571 mg/kg, and inhalation (dust/mist) ATE value of 5.2 mg/L.
  12. Correct the disclosure of misleading information regarding the LD50 (rat, inhalation) value for the ingredient “acetic acid, butyl ester”.
  13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12096
Date of compliance undertaking: 2019-10-23

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the additional hazard classification of “Acute Toxicity (Oral) — Category 4”.
  3. Disclose the additional symbol and/or name of the symbol for “Exclamation mark” on the SDS.
  4. Disclose the information elements concerning the additional hazard and precautionary statements.
  5. Correct the disclosure of misleading information with respect to personal protective equipment for first aid measures.
  6. Disclose the applicable information for “Personal precautions, protective equipment and emergency procedures” under section 6, “Accidental release measures”.
  7. Correct the disclosure of misleading information regarding the precautionary statement in section 7.
  8. Disclose an adequate product odour.
  9. Disclose the calculated product oral ATE value of 1 640 mg/kg (0% unknown).
  10. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the confidential ingredient “partially fluorinated alcohol substituted glycol”.
  11. Disclose symptoms related to the physical, chemical and toxicological characteristics.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  13. Correct the disclosure of misleading information regarding acute toxicity.
  14. Disclose the date of the latest revision.
RN: 12155
Date of compliance undertaking: 2019-10-18

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Remove CANUTEC’s emergency telephone number.
  3. Disclose the additional hazard classifications of “Serious Eye Damage — Category 1” and “Skin Irritation — Category 2”.
  4. Disclose the information elements concerning the additional hazard and precautionary statements.
  5. Disclose the symbol and/or name of the symbol for “Exclamation mark” on the SDS.
  6. Disclose the signal word “Danger”.
  7. Correct the disclosure of misleading information in section 2.
  8. Correct the disclosure of misleading information regarding accidental release measures.
  9. Disclose “Wash … thoroughly after handling” in section 7.
  10. Disclose the incompatible material(s).
  11. Disclose an adequate product odour.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  13. Disclose the calculated product oral ATE value of 3 089 mg/kg (20% unknown) and inhalation (dust/mist) ATE value of 9.0 mg/L (40% unknown).
  14. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the confidential ingredients “amine oxide #1” and “alcohol ethoxylate”.
  15. Disclose the likely routes of exposure in section 11 “Toxicological information”.
  16. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  17. Disclose the date of the latest revision.
RN: 12185
Date of compliance undertaking: 2019-10-31

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose an adequate emergency telephone number.
  4. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Single Exposure — Category 1”.
  5. Disclose the percent of unknown toxicity of “2%” and “43%” for the calculated product oral and dermal ATE values, respectively.
  6. Disclose the additional applicable common names and synonyms for the ingredient “diethylene glycol”.
  7. Correct the disclosure of misleading information regarding first aid measures.
  8. Correct the disclosure of misleading information regarding potential inhalation acute health effects.
  9. Disclose the product’s melting point/freezing point.
  10. Disclose the product’s reactivity.
  11. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  13. Disclose the calculated product oral ATE value of 485 mg/kg (2% unknown).
CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended SDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the SDS reviewed by the screening officer and the date of the order.

RN: 9858
Date of order: 2019-11-07

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose the Canadian initial supplier identifier.
  3. Disclose the symbol and/or name of the symbol for “Exclamation mark” on the SDS.
  4. Correct the disclosure of misleading information regarding accidental release measures.
  5. Correct the disclosure of misleading information regarding handling and storage.
  6. Disclose conditions for incompatibilities of the hazardous product.
  7. Disclose an accurate product colour.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the calculated product oral ATE value of 4 630 mg/kg (25% unknown).
RN:10323
Date of order: 2019-11-07

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the telephone number of the Canadian initial supplier.
  4. Disclose the additional hazard classification of “Skin Corrosion — Category 1”.
  5. Disclose the percent of unknown toxicity for the calculated product oral ATE value.
  6. Disclose the additional applicable common names and synonyms for the ingredient “butyl alcohol”.
  7. Correct the disclosure of misleading information on first aid measures.
  8. Correct the disclosure of misleading information on suitable extinguishing media.
  9. Disclose the nature of the hazardous combustion products.
  10. Disclose information on special precautions for firefighters.
  11. Correct the disclosure of misleading information with respect to personal protective equipment in section 7 of the SDS.
  12. Disclose the incompatibilities of the hazardous product.
  13. Disclose an ACGIH–TWA of 0.1 ppm and an ACGIH–STEL of 0.3 ppm exposure limits for the ingredient “formaldehyde”.
  14. Disclose a dermal and respiratory sensitization notation for the ACGIH exposure limits for the ingredient “formaldehyde”.
  15. Disclose the appropriate information under the subheadings “Boiling Point/Range” and “Autoignition Temperature”.
  16. Disclose “static discharge” as a condition to avoid.
  17. Disclose “chromium trioxide” as an incompatible material.
  18. Disclose the symptoms “skin burns”.
  19. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  20. Disclose the calculated product oral ATE value of 2 730 mg/kg and dermal ATE value of 4 140 mg/kg.
RN: 10366
Date of order: 2019-10-17

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Single Exposure — Category 1 (stomach, lungs, kidneys and central nervous system)”.
  4. Disclose the symbol and/or name of the symbol for “Health hazard” on the SDS.
  5. Disclose the additional applicable common names and synonyms for the ingredient “isopropanol”.
  6. Disclose information on the special protective equipment and precautions for firefighters.
  7. Correct the disclosure of misleading information regarding suitable extinguishing media.
  8. Disclose an accurate product colour.
  9. Disclose “ingestion” as an additional likely route of exposure.
  10. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  11. Disclose the calculated product oral ATE value of 6 897 mg/kg (0% unknown) and dermal ATE value of 4 717 mg/kg (0% unknown).
  12. Correct the disclosure of misleading information regarding the LD50 (rabbit, dermal) value for the confidential ingredient “ethoxylated alcohols” and the LD50 (rat, oral) value for the ingredient “isopropanol”.
RN: 12093
Date of order: 2019-11-23

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the additional hazard classification of “Skin Corrosion — Category 1”.
  4. Disclose the additional applicable common names and synonyms for the ingredient “2-diethylaminoethanol”.
  5. Correct the disclosure of misleading information regarding first aid measures for skin contact.
  6. Correct the disclosure of misleading information regarding hazardous combustion products.
  7. Correct the disclosure of misleading information regarding personal protective equipment.
  8. Disclose an accurate product colour.
  9. Disclose an adequate product odour.
  10. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  11. Disclose the calculated product oral ATE value of 2 800 mg/kg.
  12. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the ingredient “morpholine”, and the LC50 (rat, inhalation [vapours]) value for the ingredient “2-diethylaminoethanol” and the confidential ingredient “amino alcohol”.
RN: 12172
Date of order: 2019-11-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose “Other hazards” on the SDS.
  4. Disclose the additional applicable common names and synonyms for the ingredients “toluene”, “distillates, petroleum, straight-run, middle”, “methylcyclohexane”, “cyclohexane”, and “xylene”.
  5. Disclose the applicable information for “the most important symptoms and effects” under section 4, “First-aid measures”.
  6. Correct the disclosure of misleading information on suitable extinguishing media.
  7. Disclose the incompatibilities of the hazardous product.
  8. Disclose the pH of the product.
  9. Disclose an adequate product odour.
  10. Disclose the calculated product oral ATE value of 5 465 mg/kg, an inhalation (vapour) ATE value of 23.12 mg/L and an inhalation (dust/mist) ATE value of 1.79 mg/L.
  11. Correct the disclosure of misleading information regarding the LC50 value for the ingredients “distillates, petroleum, straight-run, middle”, “methylcyclohexane”, and “xylene”.
  12. Correct the disclosure of misleading information regarding the LD50 value for the ingredient “xylene”.
  13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the safety data sheet (SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor (4908-B), Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant Product Identifier Subject of the Claim for Exemption Registry Number
Ingevity Corporation INDULIN XD-70 C.i. and C. of one ingredient 03348860
Nalco Canada ULC EC5627A C.i. of two ingredients 03348868
Canadian Energy Services LP Gibson Emulsifier 75% Active C.i. and C. of one ingredient 03349285
Fairville Products Inc dba Fuel Right FUEL RIGHT 30K C.i. of two ingredients 03349433
Flotek Chemistry StimOil B46 C.i. of two ingredients 03349481
Evonik Corporation Protectosil® Stone Sealer & Consolidation Treatment C.i. of one ingredient 03349640
Baker Hughes Canada Company RE33883HSO C.i. and C. of one ingredient
C.i. of one ingredient
C. of one ingredient		 03349649
DuBois Chemicals Canada Inc. IPAC 1850C C.i. and C. of two ingredients 03350024
The Lubrizol Corporation Anglamol 6043P C.i. of three ingredients 03350631
The Lubrizol Corporation Solsperse 20000 C.i. of one ingredient 03350840
Valhalla Wood Preservatives Ltd. Valhalla Lifetime® Wood Treatment non-toxic wood stain C.i. and C. of one ingredient 03350924
BASF Canada Inc. Irgastab PUR 70 C.i. and C. of two ingredients
C. of one ingredient		 03350960
Canadian Energy Services LP WRXSOL-NANOFLSH-W C.i. and C. of three ingredients 03351150
Calfrac Well Services Ltd. CalSurf™ 9750 C.i. of three ingredients 03351408
The Lubrizol Corporation POWERZOL™ 9543 C.i. of one ingredient 03351641

Note: C.i. = chemical identity and C. = concentration

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments
Name and position Order in Council
MacLean, Leslie 2019-1385
Associate Deputy Minister of Foreign Affairs and Deputy Minister for International Development, to be styled Deputy Minister of International Development  
Stewart, Robert 2019-1387
Deputy Minister of Public Safety and Emergency Preparedness, to be styled Deputy Minister of Public Safety  

December 18, 2019

Diane Bélanger
Official Documents Registrar

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby designate the following person of the Lethbridge Police Service as a fingerprint examiner:

Wesley Aaron Olsen

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby designate the following person of the Saskatoon Police Service as a fingerprint examiner:

Chelsea Shepherd

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Revocation of designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby revoke the designation of the following person of the Lethbridge Police Service as a fingerprint examiner:

Jason Darby

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Revocation of designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby revoke the designation of the following person of the Saanich Police Department as a fingerprint examiner:

Shane Michael Coughlan

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Revocation of designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby revoke the designation of the following person of the Saskatoon Police Service as a fingerprint examiner:

Frank Parenteau

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Revocation of designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby revoke the designation of the following persons of the Winnipeg Police Service as fingerprint examiners:

Ottawa, December 10, 2019

Ellen Burack
Assistant Deputy Minister
Community Safety and Countering Crime Branch

BANK OF CANADA

Statement of financial position as at November 30, 2019 (Millions of dollars) Unaudited
ASSETS Amount Total
Cash and foreign deposits   6.9
Loans and receivables
Securities purchased under resale agreements 12,815.2  
Advances 334.6  
Other receivables 4.8  
    13,154.6
Investments
Treasury bills of Canada 23,485.5  
Canada Mortgage Bonds 516.6  
Government of Canada bonds 79,009.4  
Other investments 447.7  
    103,459.2
Capital assets
Property and equipment 593.0  
Intangible assets 56.4  
Right-of-use leased assets 51.3  
    700.7
Other assets   34.1
Total assets   117,355.5
LIABILITIES AND EQUITY Amount Total
Bank notes in circulation   90,206.4
Deposits
Government of Canada 22,787.4  
Members of Payments Canada 584.4  
Other deposits 2,509.5  
    25,881.3
Securities sold under repurchase agreements   —
Other liabilities   728.1
    116,815.8
Equity
Share capital 5.0  
Statutory and special reserves 125.0  
Investment revaluation reserve 409.7  
    539.7
Total Liabilities and Equity 117,355.5

I declare that the foregoing statement is correct according to the books of the Bank.

Ottawa, December 16, 2019

Carmen Vierula
Chief Financial Officer and Chief Accountant

I declare that the foregoing statement is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, December 16, 2019

Stephen S. Poloz
Governor